Drug intelligence / Profile preview

NM-201

Development stage: Preclinical
Lead developer: Neuramedy
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Parenteral

Overview

NM-201 is a blood-brain barrier (BBB)-penetrating monoclonal antibody currently in the discovery phase for the treatment of Parkinson's disease and other central nervous system (CNS) disorders. Developed by Neuramedy, the drug is designed to target Toll-like receptor 2 (TLR2) in the brain. TLR2 activation by misfolded proteins, such as alpha-synuclein, is a key driver of neuroinflammation and neuronal damage in neurodegenerative diseases. By antagonizing TLR2, NM-201 aims to suppress microglial activation and neuroinflammatory pathways, potentially slowing disease progression.

Targets

TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on NM-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM-201.

Explore the full profile